Is Croda International stock a buy right now?
As of early May 2025, Croda International plc shares trade at approximately 3,001p on the London Stock Exchange, with an average daily trading volume of around 566,340 shares, highlighting consistent investor interest. The past twelve months have challenged Croda, with the shares correcting by over a third; however, the Q1 2025 results signal a constructive shift. Group sales advanced by 8%, propelled by strength across Life Sciences, Consumer Care, and Industrial Specialties, while a cost-saving programme is on track to deliver £25 million in annualized benefits. Notably, Croda has inaugurated a new lipids manufacturing facility in the US and continues to benefit from growing demand in the crop protection and biopharma markets. Sector activity remains buoyant, especially in specialty chemicals, where innovation and regional demand are decisive drivers. Market sentiment is turning cautiously optimistic, thanks to robust Q1 operational momentum and a reaffirmed full-year outlook. The consensus target price, set at 3,901p by more than 32 national and international banks, implies a constructive view on Croda’s medium-term potential. For UK-based investors, Croda’s eligibility for Stocks and Shares ISAs and SIPPs, paired with a reliable dividend, makes it a compelling candidate for portfolio consideration in these evolving market conditions.
- Resilient Q1 2025 sales growth across all business segments, signalling operational momentum.
- Strong global presence, operating in 39 countries with diversified revenue streams.
- Robust dividend yield of 3.73%, supporting total shareholder return.
- Advances in biopharma and crop protection markets underpin medium-term growth prospects.
- On track to achieve £25 million in cost savings, enhancing profitability in 2025.
- Recent year-over-year share price decline may limit immediate upside for some investors.
- Recovery in consumer health and veterinary segments remains gradual, demanding ongoing monitoring.
- What is Croda International?
- How much is Croda International stock?
- Our full analysis on Croda International </b>stock
- How to buy Croda International stock in United Kingdom?
- Our 7 tips for buying Croda International stock
- The latest news about Croda International
- FAQ
Why trust HelloSafe?
At HelloSafe, our expert has been monitoring the performance of Croda International for over three years. Each month, hundreds of thousands of users in the United Kingdom rely on us to interpret market trends and highlight the best investment opportunities. Our analyses are intended for informational purposes only and do not constitute investment advice. In line with our ethical charter, we have never been, and will never be, paid by Croda International.
What is Croda International?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United Kingdom | UK-based company with a strong international presence in 39 countries. |
| 💼 Market | London Stock Exchange (LSE) | Listed on the LSE under ticker CRDA, offering good liquidity for investors. |
| 🏛️ ISIN code | GB00BJFFLV09 | Unique identifier confirming eligibility for ISA and SIPP accounts in the UK. |
| 👤 CEO | Steve Foots | Steve Foots has led Croda since 2012, ensuring stability and strategic continuity. |
| 🏢 Market cap | £4.19 billion | Croda's market value has declined but remains sizeable for the specialty chemicals sector. |
| 📈 Revenue | £442 million (Q1 2025) | Q1 revenue up 8% year-on-year, signaling early recovery and improved end-market demand. |
| 💹 EBITDA | Not disclosed (Q1 2025) | EBITDA not reported; investors should watch for full-year results for clearer visibility. |
| 📊 P/E Ratio (Price/Earnings) | 26.44 | Above average; reflects earnings pressure and high growth expectations for the sector. |
How much is Croda International stock?
The price of Croda International stock is rising this week. As of now, the share trades at £30.01, reflecting a 0.17% gain over the past 24 hours and a robust 4.9% increase in the last week.
| Market Capitalisation | Average 3-Month Volume | P/E Ratio | Dividend Yield | Beta |
|---|---|---|---|---|
| £4.19 billion | 566,340 shares | 26.44 | 3.73% | 0.89 |
The stock shows a P/E ratio of 26.44, a dividend yield of 3.73%, and a beta of 0.89, highlighting moderate volatility. Investors may find Croda appealing for its balanced combination of income and potential recovery in the UK specialty chemicals sector.
Compare the best brokers in the UK!Compare brokersOur full analysis on Croda International stock
Having thoroughly reviewed Croda International’s latest financial results alongside its share price evolution over the last three years, our analysis aggregates financial, technical, and market data—benchmarked with key competitors—through rigorously refined algorithms. In this report, we examine why Croda International, a leader in the specialty chemicals sector, is beginning to reflect compelling value signals for investors seeking resilient exposure to Life Sciences and Consumer Care. So, why might Croda International stock once again become a strategic entry point into the specialty chemicals and life sciences sector in 2025?
Recent Performance and Market Context
Over the past year, Croda International (LSE: CRDA) has experienced considerable volatility, with its share price retreating approximately 35.76% to settle at 3,001.00p as of early May 2025. YTD, the stock remains down 17.99%—a reflection of broader sector rotation and persistent macroeconomic headwinds. Yet, a notable reversal has materialised in recent sessions: the stock has posted a solid 4.9% gain this past week and is showing early signs of bottoming out after an extended correction.
This improvement coincides with the Q1 2025 results announcement: Group sales climbed 8% year-on-year (9% at constant currency), buoyed by robust volume growth across all business units—Consumer Care, Life Sciences, and Industrial Specialties. Particularly encouraging is the double-digit increase (10–11%) in Life Sciences, a segment central to Croda’s transformation strategy.
Sector-wide, specialty chemicals are witnessing a phase of recovery as supply chains normalise and agricultural input markets—especially crop protection in Europe—rebound. Coupled with a stabilising interest rate environment and a targeted cost-optimisation plan, Croda is well placed for renewed outperformance.
- Key recent positives:
- Robust Q1 growth across all divisions
- Recovery in core end-markets (notably agriculture and biopharma)
- New lipid manufacturing facility launched in the US, expanding high-margin capabilities
- Effective execution of a £25 million cost savings programme for 2025
- Dividend yield of 3.73% with resilient balance sheet
Given this backdrop, Croda stands out among UK-listed peers for its operational agility and renewed growth trajectory.
Technical Analysis
Croda’s technical configuration currently presents promising set-up characteristics for investors seeking favourable entry points. The stock trades near its short- and medium-term moving averages:
| Moving Average | Simple MA | Exponential MA |
|---|---|---|
| 20-day | 2,769.75p | 2,847.95p |
| 50-day | 2,934.73p | 2,918.66p |
| 100-day | 3,077.04p | 3,083.61p |
| 200-day | 3,418.87p | 3,410.85p |
At a last price of 3,001.00p, Croda is showing persistence above clustered support in the 2,910–2,972p region—a level tested but not convincingly breached since late March. These strong support zones have thus far attracted renewed buying and allowed for consolidation despite the prevailing bear trend.
| Momentum Indicator | Value | Signal |
|---|---|---|
| RSI (14 days) | 58.21 | Neutral/mid-range |
| MACD (12,26,9) | 19.03 (negative) | Flattening; possible bullish divergence |
| MA Consensus | 7 bullish vs 5 bearish | Bullish tilt |
Importantly, as the price edges towards the immediate resistance cluster (3,034–3,096p), a breakout above this band could validate a shift in medium-term structure, opening a technical pathway towards the 3,400p area (200-day MA).
Trading volume has remained robust, supporting the notion that recent accumulation is institutionally driven. For investors seeking exposure during periods of inflection, Croda appears to be establishing a classic technical base.
Fundamental Analysis
From a fundamental standpoint, Croda’s credentials remain persuasive despite the recent share price weakness—a classic scenario among high-quality compounders in cyclical sectors.
| Metric | Q1 2025 Result | Remarks |
|---|---|---|
| Group sales growth | 8% YoY (9% constant FX) | Volume expansion across all segments |
| Life Sciences growth | 10-11% | Segment driving transformation |
| Consumer Care growth | 8% | Supported by new product launches |
| Pre-tax profit | In line | Despite cost headwinds |
| P/E ratio | 26.44 | Discount vs. previous years |
| Dividend yield | 3.73% (110p) | Strong cash return |
- Structural strengths:
- Leading global supplier of specialty ingredients—particularly for high-value, less commoditised niches within Consumer Care and agriscience.
- Strong competitive moat built on R&D, intellectual property, and deep, local customer relationships (80% of Consumer Care revenue derives from direct local clients).
- Robust global footprint with manufacturing and innovation sites in strategic markets (39 countries, supported by 6,027 employees).
- Recent strategic pivot away from commoditised industrials to focus on Life Sciences and Consumer Care is beginning to deliver measurable top-line and margin improvement.
In essence, Croda’s core proposition—a blend of sustainable innovation, customer intimacy, and operational discipline—continues to justify renewed investor interest.
Volume and Liquidity
Trading volumes in Croda have remained notably elevated, with an average daily turnover of 566,340 shares even during the recent corrective phase. Crucially, this sustained liquidity—even amid price pressure—underscores continued institutional engagement and signals enduring market confidence.
With 142.54 million shares in free float and significant stakes held by long-term institutional investors (Norges Bank, MFS, Mawer, BlackRock), Croda exhibits a shareholder structure that favours price stability and dynamic valuation. The relatively moderate beta (0.8853) underlines the stock’s muted sensitivity to broader market drawdowns, an attractive trait for portfolio construction in uncertain times.
Moreover, Croda’s eligibility for tax-advantaged accounts (ISA, SIPP) increases its appeal to UK investors seeking to offset or mitigate capital gains/liquidity risks.
Catalysts and Positive Outlook
- Several bullish catalysts mark 2025 as a turning point in Croda’s earnings narrative:
- Operational excellence: The ongoing £25m cost-saving programme has delivered immediate impact, enhancing operating leverage and setting the stage for margin recovery.
- Innovation drive: The inauguration of a state-of-the-art lipids manufacturing facility in Pennsylvania (March 2025) cements Croda’s leadership in pharmaceutical excipients—a high-margin, rapidly expanding market.
- Local growth bias: The group is strategically realigning production and procurement to address surging local/regional demand, aligning capacity with the growing importance of onshoring and supply chain robustness.
- Sector upturn: Crop protection and biopharma end-markets are both in cyclical recovery, feeding directly into Croda’s core portfolio. Consumer Care also demonstrates steady improvement after a volatile 2024.
- Strong ESG credentials: As sustainability becomes a central investor criterion, Croda’s R&D-led approach to bio-based and environmentally benign ingredients is gaining both regulatory and customer traction.
- New leadership and strategic focus: The appointment of Stephen Oxley as CFO and Danuta Gray as Chair brings renewed governance discipline and an emphasis on shareholder value.
These dynamics, coupled with reaffirmed FY2025 guidance, point to upside potential not currently reflected in the consensus price target (3,901p, suggesting 30% appreciation vs. current levels).
Investment Strategies
- Short-term: A technical bounce at multi-month support (2,910–2,972p) allows tactical traders to position for a breakout above the 3,034–3,096p resistance corridor. Near-term catalysts such as upcoming trading updates and the first dividend payment (May 28, 2025) may trigger a re-rating.
- Medium-term: The improving margin outlook, visible cost savings, and greater market stability favour a 6–12 month accumulation strategy—especially as the broader specialty chemicals sector normalises. Any decisive move above the 200-day MA (~3,420p) would strongly reinforce a bullish structure, aligning with the projected return to pre-2023 levels.
- Long-term: For patient investors, Croda’s transition towards high-growth, IP-protected end-markets (Life Sciences, Consumer Care), strategic global footprint, and ESG leadership all support a tenable, compounding investment thesis. The current dividend yield and relative valuation provide a cushion amid ongoing volatility, suggesting a potentially attractive long-term risk/reward profile.
Optimal positioning may be achieved by scaling in at technical lows or in advance of flagged growth catalysts—leveraging Croda’s propensity for sharp recoveries once sentiment stabilises.
Is it the Right Time to Buy Croda International?
Croda International today presents a compelling confluence of factors: a resilient and diversified business model, strong first-quarter growth, proven ability to deliver cost efficiencies, robust liquidity, and a visible pipeline of earnings catalysts. The stock is consolidating at major support, with technical and fundamental signals both tilting towards a new bullish phase. A significant price correction in 2024 has reset expectations and created an entry window rarely seen for a company of Croda’s stature.
Looking ahead, Croda’s best-in-class innovation, market leadership in high-value niches, and pragmatic strategic execution position it as a potential outperformer in the Life Sciences and Consumer Care space for 2025 and beyond. For investors seeking an optimal balance of income, growth, and structural defensiveness, Croda International seems to represent an excellent opportunity. While diligence and discipline are always warranted, the current context justifies serious consideration—not only for short-term rebound potential but for robust long-term compounding.
In summary, the stage is set for Croda International to reassert its credentials as one of the UK market’s most attractive and resilient compounders—an opportunity well worth close attention from investors determined to capture the sector’s next wave of growth.
How to buy Croda International stock in United Kingdom?
Buying Croda International (CRDA) shares online is a straightforward and secure process when using a regulated broker in the UK. Investors can choose between two popular methods: spot (cash) buying, where you directly own the stock, or trading via Contracts for Difference (CFDs), which allows you to speculate on the share price with leverage. Both approaches offer flexibility and transparency, and strong UK regulations help protect investors’ interests and funds. If you’re considering investing, you’ll find a detailed broker comparison table further down the page to help you select the right platform.
Spot buying
A cash purchase of Croda International shares means you buy and own the actual shares registered in your name. This is the classic, long-term investment method, and is eligible for tax-advantaged accounts like Stocks and Shares ISAs and SIPPs. Brokers typically charge a fixed commission per order, often around £5 to £10 in the UK.
Important Example
If Croda International shares trade at £30.01 each, with £1,000 you can buy around 33 shares (£1,000 – £5 fee = £995; £995 ÷ £30.01 ≈ 33 shares).
✔️ Gain scenario:
If the share price rises by 10%, your shares are now worth £1,100.
Result: +£100 gross gain, i.e. +10% return on your investment.
Trading via CFD
CFD (Contract for Difference) trading allows you to speculate on Croda International’s share price movements without owning the underlying shares. CFDs are popular with traders looking for short-term opportunities and leverage. Fees usually include the spread (the difference between buy and sell price) and overnight financing costs if you hold the position beyond a day.
Important Example
With £1,000 and 5x leverage, you gain market exposure of £5,000.
You open a CFD position on Croda International shares.
✔️ Gain scenario:
If the stock price rises by 8%, your position gains 8% × 5 = 40%.
Result: +£400 gain on a £1,000 investment (excluding fees).
Final advice
Before investing, it’s vital to compare each broker’s fees and terms—which can vary significantly for both cash buying and CFD trading. Ultimately, your choice will depend on your investment goals: direct ownership is ideal for long-term investors, while CFDs may suit traders seeking short-term gains with leverage. For a full comparison of brokers and their fees, please consult the table lower down this page.
Is EightCap reliable?
Yes, EightCap is a trusted platform, regulated by the FCA (UK) and the ASIC (Australia). Since 2009, it has ensured the security of funds with segregated accounts and a rigorously regulated trading environment. If you are looking for a reliable broker to get started, EightCap is a safe platform, recognised in the industry.
Why choose EightCap?
EightCap combines performance and flexibility. The platform offers a wide selection of assets and tools like TradingView, perfect for demanding traders. Are you a novice? No problem: its demo accounts and innovative integrations like TradingView make learning intuitive and efficient.
What are the fees at EightCap?
At EightCap, fees depend on the account you choose: Raw accounts display spreads starting from 0 pips, with a commission of $3.5 per lot. Standard accounts, on the other hand, have slightly higher spreads but no commissions. No fees on deposits or withdrawals, for clear and controlled costs.
Who is EightCap for?
Whether you are a beginner or an experienced trader, EightCap is designed to meet your needs. Are you starting out? Take advantage of guides and demo accounts to understand the basics. Are you more advanced? Tools like TradingView and competitive spreads will allow you to go further in your strategies.
Is it easy to withdraw your money from EightCap?
Withdrawing your winnings on EightCap is simple and fast. Requests are processed within 24 hours and you can use flexible options such as bank transfer, cards or electronic wallets. Security and speed are at the heart of the service.
Is EightCap reliable?
Yes, EightCap is a trusted platform, regulated by the FCA (UK) and the ASIC (Australia). Since 2009, it has ensured the security of funds with segregated accounts and a rigorously regulated trading environment. If you are looking for a reliable broker to get started, EightCap is a safe platform, recognised in the industry.
Why choose EightCap?
EightCap combines performance and flexibility. The platform offers a wide selection of assets and tools like TradingView, perfect for demanding traders. Are you a novice? No problem: its demo accounts and innovative integrations like TradingView make learning intuitive and efficient.
What are the fees at EightCap?
At EightCap, fees depend on the account you choose: Raw accounts display spreads starting from 0 pips, with a commission of $3.5 per lot. Standard accounts, on the other hand, have slightly higher spreads but no commissions. No fees on deposits or withdrawals, for clear and controlled costs.
Who is EightCap for?
Whether you are a beginner or an experienced trader, EightCap is designed to meet your needs. Are you starting out? Take advantage of guides and demo accounts to understand the basics. Are you more advanced? Tools like TradingView and competitive spreads will allow you to go further in your strategies.
Is it easy to withdraw your money from EightCap?
Withdrawing your winnings on EightCap is simple and fast. Requests are processed within 24 hours and you can use flexible options such as bank transfer, cards or electronic wallets. Security and speed are at the heart of the service.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the FCA (United Kingdom), ASIC (Australia), and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognised for its security and transparency. According to our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don't need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while you invest.
You get access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community to exchange ideas: eToro makes investing simple, interactive and educational. It's like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of shares or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposit is free, and withdrawal is set at $5. In the event that you remain inactive for 12 months or more, a fee of $10 per month applies.
Finally, the fees charged are also clearly mentioned on its website (we can't say the same for all competitors).
Who is eToro for?
eToro is mainly aimed at beginners and intermediates, thanks to its simplicity and its educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here, with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step by step, ensuring you have permanent access to your funds. After analysing thousands of customer cases, no such problem has been reported.
Is eToro reliable?
Yes, eToro is a reliable platform, regulated by leading authorities, including the FCA (United Kingdom), ASIC (Australia), and CySEC in Europe. With over 30 million users worldwide, eToro is widely recognised for its security and transparency. According to our analysis, this broker is among the most reliable in the market, and we have not found any complaints regarding the security of funds.
Why choose eToro?
With eToro, you don't need to be an expert to get started. Its intuitive interface and unique tool, the CopyTrader, allow you to copy the best traders to learn while you invest.
You get access to thousands of assets, such as stocks, cryptos, Forex and commodities, all with an active community to exchange ideas: eToro makes investing simple, interactive and educational. It's like the Spotify of investing.
What are the fees at eToro?
eToro is transparent about its fees: no commission on the purchase of shares or ETFs. Spreads vary depending on the asset, but remain very affordable.
Deposit is free, and withdrawal is set at $5. In the event that you remain inactive for 12 months or more, a fee of $10 per month applies.
Finally, the fees charged are also clearly mentioned on its website (we can't say the same for all competitors).
Who is eToro for?
eToro is mainly aimed at beginners and intermediates, thanks to its simplicity and its educational approach. If you want to diversify your portfolio or learn by observing the best traders, this platform is ideal.
Investors looking for a modern and intuitive experience will also find their account here, with a key argument: a real variety of assets (stocks, cryptocurrencies, ETFs).
Is it easy to withdraw your money from eToro?
Yes, withdrawing your winnings from eToro is as easy as investing. With options like PayPal, bank transfer or credit card, eToro processes your requests within 1 to 3 business days.
The platform guarantees transparency of fees, and the procedure is explained step by step, ensuring you have permanent access to your funds. After analysing thousands of customer cases, no such problem has been reported.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions including the Central Bank of Ireland, ASIC (Australia) and FSA (Japan). Operating since 2006, it offers strong guarantees, including the segregation of client funds and strict adherence to international standards. With over 300,000 active users, it inspires confidence in both beginner and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. The free tutorials, demo accounts and training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don’t need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when it comes to paying.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you’re looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is an excellent choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, bank transfer or electronic wallets. Everything is designed to give you quick, clear and secure access.
Is AvaTrade reliable?
AvaTrade is a trusted broker, regulated by major institutions including the Central Bank of Ireland, ASIC (Australia) and FSA (Japan). Operating since 2006, it offers strong guarantees, including the segregation of client funds and strict adherence to international standards. With over 300,000 active users, it inspires confidence in both beginner and experienced traders.
Why choose AvaTrade?
AvaTrade combines simplicity and expertise. The free tutorials, demo accounts and training help you learn at your own pace. Advanced tools like MT4/MT5 offer endless possibilities once you progress. You don’t need to be an expert: AvaTrade adapts to you.
What are the fees at AvaTrade?
AvaTrade offers simple and affordable fees: competitive fixed spreads, no deposit or withdrawal fees, and avoidable inactivity costs with regular use. You can focus on learning and your investments, without any surprises when it comes to paying.
Who is AvaTrade for?
AvaTrade is for everyone: beginners can benefit from detailed educational content and demo accounts, while advanced traders will find tools like automated trading or Vanilla options. If you’re looking for a reliable platform to develop your skills or diversify your assets, AvaTrade is an excellent choice.
Is it easy to withdraw money from AvaTrade?
Yes, AvaTrade offers a fast and secure withdrawal process. Once your account is verified, your requests are processed within 1 to 2 business days. You can use various options such as bank cards, bank transfer or electronic wallets. Everything is designed to give you quick, clear and secure access.
Our 7 tips for buying Croda International stock
| 📊 Step | 📝 Specific tip for Croda International |
|---|---|
| Analyze the market | Review Croda International's recent recovery in Q1 2025, focusing on 8% sales growth and its strategic shift toward Life Sciences and Consumer Care. |
| Choose the right trading platform | Select a UK-regulated broker offering access to the London Stock Exchange, and ensure the platform supports Stocks and Shares ISAs for tax efficiency. |
| Define your investment budget | Assess risk by considering Croda’s recent 35% share price decline and set a budget you can comfortably invest, keeping diversification in mind. |
| Choose a strategy (short or long term) | Consider a long-term approach to benefit from Croda’s cost-saving initiatives, dividend yield, and projected core market improvement throughout 2025. |
| Monitor news and financial results | Stay updated on Croda’s quarterly reports, RNS filings, and developments such as the new US lipids facility and cost savings progress. |
| Use risk management tools | Set stop-loss orders at support levels (e.g., around 2,910p) to manage downside risk, and periodically rebalance based on technical signals. |
| Sell at the right time | Evaluate exiting or taking profits when approaching resistance levels (e.g., 3,035p) or before major macroeconomic or company announcements. |
The latest news about Croda International
Croda International reported a robust 8% increase in group sales for Q1 2025, signalling renewed momentum. The company’s first-quarter results, released on April 23, showed group sales reaching £442 million, representing an 8% rise versus the prior year (9% at constant currency). This growth was underpinned by solid volume increases across all three of its operating segments, with notable strength in both the Consumer Care division (up 8%)—driven by enduring demand from UK and wider European clients—and the Life Sciences segment, which advanced 10%. Industrial Specialties also delivered healthy volume recovery. Management confirmed pre-tax profit was in line with expectations and reaffirmed full-year guidance, sending a constructive signal to UK investors regarding operational stability and resilience.
A £25 million cost-savings programme for 2025 remains on track, supporting improved profit margins and operational leverage. Croda’s management team reaffirmed its commitment to previously announced cost-saving initiatives, with the firm set to realise annualised savings of £25 million this year. Progress is especially visible across the UK manufacturing network, where asset utilisation rates have improved, driving efficiencies at key sites. This focus on cost discipline and leaner operations is directly relevant for analysts watching the company’s margin recovery and cash flow generation within the UK context.
Croda’s dividend yield now stands at 3.73%, with the next payment scheduled for May 28, offering reliable income for UK shareholders. The board declared an annual dividend of 110 GBX per share, with an ex-dividend date of April 10, 2025. Croda’s sustained dividend policy reinforces its appeal for income-focused UK investors, especially those utilising tax-advantaged wrappers like Stocks & Shares ISAs and SIPPs. The company’s stated commitment to shareholder returns, even during a period of broader sector volatility, is seen as a stabilising influence on the share price.
Technical signals have turned cautiously positive, driven by a 4.9% share price gain over the last week and improving momentum. Croda’s stock has rebounded strongly in recent sessions, outperforming its sector peers and adding nearly 5% week-on-week to reach 3,001.00p. This rally has brought it above key short-term moving averages, with technical consensus from moving averages registering a bullish bias. Although some technical indicators remain neutral or bearish, the shift towards positive sentiment combined with stable fundamentals is increasing constructive analyst commentary within the UK market.
Continued growth in local UK and European crop protection and biopharma markets bolsters Croda’s revenue outlook. The company specifically highlighted robust recovery in the European crop protection sector and sustained momentum in biopharma—a direct result of Croda’s long-term investments in life sciences infrastructure and innovation capabilities. Croda’s strong exposure to local and regional clients, who account for around 80% of Consumer Care revenues, ensures that improvements in domestic demand are swiftly reflected in top-line performance. This strategic alignment between Croda’s operations and UK market needs remains a core competitive advantage and positive market signal.
FAQ
What is the latest dividend for Croda International stock?
Croda International currently pays a dividend to shareholders. The next dividend payment is scheduled for 28 May 2025, with an annual dividend of 110.00 GBX per share. With a dividend yield of 3.73%, Croda offers an attractive income stream for investors. Historically, Croda maintains a steady distribution policy, making regular payments even during challenging years.
What is the forecast for Croda International stock in 2025, 2026, and 2027?
Based on current levels, Croda International’s share price is projected to reach 3,901.30p at the end of 2025, 4,501.50p by the close of 2026, and 6,002.00p heading into 2027. These optimistic projections reflect continued recovery, growth in life sciences and biopharma, and positive industry fundamentals. Recent cost-saving initiatives and rising demand in key sectors further boost confidence in Croda’s long-term outlook.
Should I sell my Croda International shares?
If you already hold Croda International shares, staying invested may be appropriate. The company has demonstrated strategic resilience, with recent sales growth and ongoing cost efficiencies despite past price volatility. Croda’s positioning in high-growth specialty chemicals and a steady dividend policy signal potential for mid- to long-term recovery. Fundamental indicators and recent results suggest continued value for patient investors.
Are Croda International shares eligible for a Stocks and Shares ISA in the UK, and how are dividends taxed?
Yes, Croda International shares are eligible for inclusion in a UK Stocks and Shares ISA, which allows investors to benefit from tax-free returns on income and capital gains. Dividends received within an ISA are not subject to UK income tax, and there is no withholding tax for UK residents, making this a tax-efficient way to hold Croda shares.
What is the latest dividend for Croda International stock?
Croda International currently pays a dividend to shareholders. The next dividend payment is scheduled for 28 May 2025, with an annual dividend of 110.00 GBX per share. With a dividend yield of 3.73%, Croda offers an attractive income stream for investors. Historically, Croda maintains a steady distribution policy, making regular payments even during challenging years.
What is the forecast for Croda International stock in 2025, 2026, and 2027?
Based on current levels, Croda International’s share price is projected to reach 3,901.30p at the end of 2025, 4,501.50p by the close of 2026, and 6,002.00p heading into 2027. These optimistic projections reflect continued recovery, growth in life sciences and biopharma, and positive industry fundamentals. Recent cost-saving initiatives and rising demand in key sectors further boost confidence in Croda’s long-term outlook.
Should I sell my Croda International shares?
If you already hold Croda International shares, staying invested may be appropriate. The company has demonstrated strategic resilience, with recent sales growth and ongoing cost efficiencies despite past price volatility. Croda’s positioning in high-growth specialty chemicals and a steady dividend policy signal potential for mid- to long-term recovery. Fundamental indicators and recent results suggest continued value for patient investors.
Are Croda International shares eligible for a Stocks and Shares ISA in the UK, and how are dividends taxed?
Yes, Croda International shares are eligible for inclusion in a UK Stocks and Shares ISA, which allows investors to benefit from tax-free returns on income and capital gains. Dividends received within an ISA are not subject to UK income tax, and there is no withholding tax for UK residents, making this a tax-efficient way to hold Croda shares.
